The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development

(2018) Zev A. Binder et al.   CANCER CELL

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice

(2018) Jing Wang et al.   PHARMACOLOGICAL RESEARCH

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

(2017) Chenglong Yue et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

(2017) Gao Guo et al.   NATURE NEUROSCIENCE

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

(2017) Eskil Eskilsson et al.   NEURO-ONCOLOGY

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

(2017) Sam Butterworth et al.   MedChemComm

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

(2016) Tikvah K. Hayes et al.   CANCER CELL

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

(2016) Xuejiao Liu et al.   Journal of Hematology & Oncology

Epidermal growth factor receptor targeting and challenges in glioblastoma

(2016) Amy Haseley Thorne et al.   NEURO-ONCOLOGY

SRPX2 Enhances the Epithelial–Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells

(2015) Haitao Tang et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity

(2015) Mingshan Niu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma

(2015) Y. Ma et al.   CLINICAL CANCER RESEARCH

Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression

(2015) Mingshan Niu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

(2015) Yuliana Yosaatmadja et al.   JOURNAL OF STRUCTURAL BIOLOGY

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling

(2015) Feng Liu et al.   MOLECULAR CELL

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Toward precision medicine in glioblastoma: the promise and the challenges

(2015) Michael D. Prados et al.   NEURO-ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

(2015) Emily Padfield et al.   Frontiers in Oncology

Autophagy contributes to gefitinib-induced glioma cell growth inhibition

(2014) Cheng-Yi Chang et al.   EXPERIMENTAL CELL RESEARCH

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

(2014) M. Raymond V. Finlay et al.   JOURNAL OF MEDICINAL CHEMISTRY

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma

(2013) L Li et al.   ONCOGENE

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

(2012) Arnab Chakravarti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

(2008) A. A. Brandes et al.   CLINICAL CANCER RESEARCH

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY